FEATURED

BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide Placebo-adjusted Increase in Growth Velocity of 1.6 cm/yr (p<0.0001) in Children Treated with Vosoritide Over One Year Pre-submission Meetings with Health Authorities Planned for H1 2020 to Discuss Marketing Applications SAN RAFAEL, Calif., Dec.